Pegfilgrastim-Bmez(Clariant Ag)

DUBLIN, Feb. 9, 2024 /PRNewswire/ -- The "Injectable Hematology Growth Factors Report" has been added to ResearchAndMarkets.com's offering. Understanding the rapidly advancing sector of injectable hematology growth factors is crucial for stakeholders in the healthcare industry. The latest comprehensive report evaluates the intersection of technology, products, and key players that are shaping this dynamic segment, with particular emphasis on devices designed for patient self-administration. The study presents an in-depth examination of the evolving therapeutic care landscape, highlighting significant developments in the treatment of conditions such as anemia, neutropenia, and thrombocytopenia. It analyzes the shift from traditional vials to prefilled injection devices, a trend that is likely to gain momentum over the following five years, emphasizing the market forces driving this change. Key Highlights from the Report: An in-depth analysis of device strategies and product development factors influencing the injectable hematology growth factors delivery systems. Insight into market dynamics and demographics, underpinning industry growth. An evaluation of therapeutic demand drivers across pivotal segments in healthcare. Comprehensive market data and forecast trends to inform strategic decisions. Profiles of sector participants including business strategies and corporate associations. An assessment of how alliances and partnerships affect the commercialization of drug products. Insights into the economic, technological, and regulatory factors impacting the market. Healthcare administrators, investors, and other stakeholders will benefit from this study's findings that not only chart current market conditions but also project future industry directions. It serves as a critical resource for decision-makers aiming to understand and capitalize on the opportunities presented within this segment. The report's findings are pivotal for a broad spectrum of healthcare professionals, including pharmaceutical decision-makers, device developers, healthcare marketers, and supply chain entities. It is particularly geared towards empowering chronically ill patients and enhancing safety protocols through revolutionary drug delivery methods. Stakeholders are poised to gain substantial insights into the strategies propelling the adoption of injectable hematologic treatments, facilitating informed decisions that align with the compelling trends of self-administered therapeutic care. Discover the Future of Injectable Hematology Treatments As the healthcare industry continues its inexorable march towards more patient-centric and self-managed treatment options, understanding the nuances and intricacies of injectable hematology growth factor treatments becomes ever more critical. The recent report provides these vital insights, demarking a clear view of the path forward. Stay informed on the latest in healthcare advancements and market opportunities. For further information and to explore the depth of this report, interested parties are encouraged to delve into the comprehensive analysis that awaits them. Key Topics Covered: Hematology Market Dynamics Competitive Factors Proliferation of Biological Drugs Product Manufacturers Hematology Growth Factors Devices for Administering Injectable Growth Factors Device Selection - Stability and Material Issues Competitive Landscape Prefilled Syringes Pen Injectors Dual Chamber Pens Emerging Devices Injectable Hematology Growth Factors - Product Assessment Abseamed Accofil Aranesp Binocrit Biograstim Biopoin Epoetin Alfa Hexal Eporatio Filgrastim Hexal Fulphila Granix Grastofil Mircera NeoRecormon Neulasta Neupogen Nivestim Ratiograstim Retacrit Rolvedon Silapo Tevagrastim Udenyca (Coherus BioSciences) Zarzio Ziextenzo Market Assessment Anemia Hematopoietic Stem Cell Transplant Advanced Kidney Disease Neutropenia Predonation of Autologous Blood Company Profiles Companies Mentioned AbZ-Pharma Accord Healthcare Amgen Genentech Hexal AG Medice Arzneimittel Mylan International Novartis Pfizer Ratiopharm Rentscler Biotechnologie Roche Sandoz Stada Arzneimittel AG Teva Pharmaceuticals For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

ZURICH/BERLIN, Nov 5 (Reuters) - The Swiss blue-chip SMI was seen opening 0.2% higher at 10,357 points on Tuesday, according to premarket indications by bank Julius Baer . Here are some of the main factors that may affect Swiss stocks: ADECCO Adecco Group said “challenging market conditions in Europe and the U.S.” were weighing on the temporary staffing company’s results as it reported a 2% drop in third-quarter revenue. Adecco Sells Soliant Health For $612 Mln To Olympus Partners BANKING Europe’s private banks and asset managers are facing a crisis as business models are hollowed out by negative interest rates, the chief executive of Edmond de Rothschild told the Financial Times. OC OERLIKON CORPORATION AG PFAEFFIKON The Swiss industrial group reported its third-quarter revenue and core profit slightly below analysts’ expectations on Tuesday, citing continued market challenges. Oerlikon’s third-quarter revenue declined to 633 million euros ($704 million), while its earnings before interest, taxes, amortisation and depreciation (EBITDA) dropped to 84 million euros, the Swiss group said. COMPANY STATEMENTS * Novartis AG: Sandoz receives U.S. FDA approval for long-acting oncology supportive care biosimilar Ziextenzo (pegfilgrastim-bmez); Ziextenzo is indicated to decrease incidence of febrile neutropenia, one of most serious side effects of chemotherapy * EFG International AG - Nominates Peter Fanconi as its new chair and Amy Yip as a new member of the board of directors * Luzerner Kantonalbank AG: 9-month net profit of 151.8 million CHF (up 3.2% from year ago) * Peach Property Group AG: in medium term, actual rental income targeted to increase to chf 60 million due to integration of new portfolio; EBT in fiscal year 2019 expected to increase to more than chf 100 million, an increase of 75 percent year-on-year; outlook 2019: pre-tax profits to more than chf 100 million for fiscal year 2019, significantly exceeding expectations * LEM Holding SA: H1 sales decreased by 5.9% to CHF 159.1 million (CHF 169.0 million); net profit was down by 8.2% at CHF 25.1 million (CHF 27.3 million) * Dufry AG: Turnover in first nine months of 2019 reached CHF 6,682.0 million versus 6,560.7 million year ago * Ypsomed Holding AG: consolidated total turnover of chf 190.6 million during first half-year of business year 2019/20; h1 EBIT from continuing operations increased by 71%, h1 net profit amounted to chf 7.6 million (previous year: chf 56.1 million, incl. effects discontinued operations) * Burckhardt Compression confirmed its full-year guidance of 600-640 million Swiss francs in sales and slightly higher margins after reporting a rise in sales and income. * Santhera Pharmaceuticals named Dario Eklund as CEO. Thomas Meier will continue as a board member and will chair a newly formed board of director’s scientific committee. RESEARCH Straumann Holding AG: HSBC raises target price to Sfr 1,000 from 960 ECONOMY No major Swiss economic data scheduled (Reporting by Zurich newsroom and Berlin Speed Desk)